Biotechnology

Alpha Cognition

Alpha Cognition released FY2026 Q1 earnings on May 14 After-Market (EST), actual revenue USD 3.534 M (forecast USD 3.571 M), actual EPS USD -0.3199 (forecast USD -0.395)

Alpha Cognition to Release FY2026 Q1 Earnings on May 14 After-Market EST, Forecast Revenue USD 3.63 M, EPS USD -0.395

Alpha Cognition released FY2025 earnings on March 26 After-Market EST, actual revenue USD 10.22 M (forecast USD 10.66 M), actual EPS USD -1.1699 (forecast USD -1.115)

Alpha Cognition released FY2025 Q4 earnings on March 26 After-Market EST, actual revenue USD 2.793 M (forecast USD 3.215 M), actual EPS USD -0.3038 (forecast USD -0.27)

Alpha Cognition to Release FY2025 Q4 Earnings on March 26 After-Market EST, Forecast Revenue USD 3.214 M, EPS USD -0.27

Alpha Cognition released FY2025 9 Months Earnings on November 13 After-Market EST, actual revenue USD 7.427 M, actual EPS USD -1.0799

Alpha Cognition released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 2.841 M (forecast USD 2.304 M), actual EPS USD -0.3037 (forecast USD -0.47)

Alpha Cognition to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast Revenue USD 2.299M, EPS USD -0.47

Alpha Cognition released FY2025 Semi-Annual Earnings on August 14 After-Market EST, with actual revenue of USD 4.586 M and EPS of USD -0.7799

Alpha Cognition released FY2025 Q2 earnings on August 14 After-Market EST, actual revenue USD 1.658 M (forecast USD 1.664 M), actual EPS USD -0.6547 (forecast USD -0.46)

Alpha Cognition to Release FY2025 Q2 Earnings on August 14 After-Market EST, Forecast Revenue USD 1.678 M, EPS USD -0.46

Alpha Cognition to Present New Clinical Data on Alzheimer's Drug at Conference

Alpha Cognition Reports Positive Preclinical Results for ALPHA-1062 in mTBI Treatment

Alpha Cognition Inc. launches ZUNVEYL and secures Medicare coverage

Alpha Cognition released FY2025 Q1 earnings on May 15 After-Market EST, actual revenue USD 2.929 M (forecast USD 994.54 K), actual EPS USD -0.1252 (forecast USD -0.78)

Alpha Cognition Reports Q1 2025 Earnings

Alpha Cognition to release FY2025 Q1 earnings on May 15 After-Market EST, forecast revenue USD 994.54 K, EPS USD -0.78

Alpha Cognition Inc. Strong Performance, Successful NASDAQ Listing and $52.8 Million Raised

Alpha Cognition released FY2024 Q4 earnings on March 31 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5205 (forecast USD -0.48)

Alpha Cognition released FY2024 Annual Earnings on March 31 After-Market EST, Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -2.0404 (Forecast USD -0.08)

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

PTGX

ACOG

ARKG

Genvor, Inc. has appointed Donald Kalkofen as Chief Financial Officer to lead its financial strategy as the company pursues growth in agriculture and human health markets. Kalkofen brings over 20 years of experience in public company finance, including successful IPOs. He previously served as CFO at Alpha Cognition and Protagonist Therapeutics, guiding them through significant growth and public listings. Genvor aims to leverage his expertise to strengthen its financial foundation and advance its dual-market commercialization plans.

StockTitan

Protagonist Therap

Health Care Select Sector SPDR

VanEck Biotech ETF

SPDR S&P Biotech

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Genvor Appoints Donald Kalkofen as Chief Financial Officer | GNVR Stock News

Alpha Cognition (NASDAQ:ACOG) reported a 40% revenue growth in Q1 2026, achieving $3.5 million in net product revenues, primarily from Zunvil's commercialization. The company aims for operating profitability by 2027 and has a strong cash position of $54.2 million. Key initiatives include launching three real-world studies for Zunvil and expanding the customer-facing team to 60 members. Alpha Cognition also strengthened its intellectual property with two new patents and anticipates key clinical data milestones in Q3 2026.

benzinga_article

Full Transcript: Alpha Cognition Q1 2026 Earnings Call

DARE

SHPH

WGRX

PIII

HCWB

In Thursday's after-market session, HCW Biologics saw a significant gain of 70.3%, reaching $0.57, following the release of Q1 earnings. Other notable gainers included P3 Health Partners (+47.14%), Alpha Cognition (+10.73%), and Shuttle Pharmaceuticals (+9.64%). Conversely, Dare Bioscience experienced the largest decline at 30.1%, with other losers including Aardvark Therapeutics (-15.16%) and Wellgistics Health (-10.11%). All companies reported Q1 earnings today, impacting their stock performance.

Dare Bioscience

Shuttle Pharmaceuticals

Wellgistics Health

P3 Health Partners

HCW Biologics

Voyager Therap

Avita Medical

Aardvark Therapeutics

Zentek

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's After-Market Session

Analyst Ram Selvaraju of H.C. Wainwright has reaffirmed a Buy rating on Alpha Cognition Inc, maintaining a price target of $18. The early settlement with Galantos enhances financial flexibility by eliminating future royalty payments, simplifying cash outflows, and strengthening the company's economic position. Selvaraju believes Alpha Cognition is adequately funded through its projected cash flow break-even point, reducing financing risk. Additionally, the appointment of Bethany Sensenig to the board is expected to enhance strategic execution and governance. Craig-Hallum also initiated coverage with a Buy rating and a $14 price target.

- Analyst Ram Selvaraju from H.C. Wainwright reiterated a buy rating on Alpha Cognition Inc, maintaining a target price of $18.00 based on improved financial flexibility and streamlined obligations.  
- The resolution with Galantos is expected to simplify future cash outflows by approximately 40%, enhancing the company's long-term economic position without significantly reducing current cash reserves.  
- Additionally, the appointment of experienced executive Bethany Sensenig to the board is anticipated to strengthen strategic execution and governance, supporting a favorable risk-return outlook for the stock.

Tip Ranks

Alpha Cognition: Buy Rating Reaffirmed as Early Galantos Settlement Enhances Financial Flexibility; $18 Price Target Maintained

Alpha Cognition Inc. (NASDAQ:ACOG) experienced a significant drop in short interest, falling 37.3% to 205,331 shares as of April 15th. Currently, 1.1% of the company's stock is sold short, with a short-interest ratio of 2.8 days based on an average daily trading volume of 73,049 shares. The stock opened at $6.86, with a market cap of $149.34 million. Analysts have issued a "buy" rating with a target price of $14.00, while the consensus price target is $16.00. The company focuses on treatments for neurodegenerative diseases.

Market Beat

Short Interest in Alpha Cognition Inc. (NASDAQ:ACOG) Drops By 37.3%

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig | ACOG Stock News

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig | ACOG Stock News

Alpha has appointed Bethany Sensenig as a director, effective April 15, 2026. Sensenig has a strong background, having served as the former CFO & Head of Operations at Radius Health and held various finance roles at other companies, including Biogen. The reason for her appointment and any replacement information have not been disclosed. This change was filed with the SEC under Alpha Cognition Inc. [ACOG].

Alpha Cognition(ACOG.US)

Genvor Appoints Donald Kalkofen as Chief Financial Officer | GNVR Stock News

Full Transcript: Alpha Cognition Q1 2026 Earnings Call

12 Health Care Stocks Moving In Thursday's After-Market Session

Alpha Cognition: Buy Rating Reaffirmed as Early Galantos Settlement Enhances Financial Flexibility; $18 Price Target Maintained

Short Interest in Alpha Cognition Inc. (NASDAQ:ACOG) Drops By 37.3%

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig | ACOG Stock News

Bethany Sensenig appointed to Alpha board as director